Tocilizumab (Actemra®)

Status
To Patients
Condition
Systemic Sclerosis ILD
Intervention Type
Subcutaneous (SC) Injection
Funder Type
Industry

Drug Details

Tocilizumab (Actemra®) is a prescription medicine called an interleukin-6 (IL-6) receptor antagonist. The U.S. Food and Drug Administration (FDA) approved Actemra® (tocilizumab) subcutaneous injection for slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), a debilitating condition with limited treatment options. Actemra® is the first biologic therapy approved by the FDA for the treatment of the disease.

More Information

ACTEMRA.com

 

footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >